amiodarone has been researched along with Drop Attack in 44 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Induction of rapid ventricular tachycardia or fibrillation during therapy with amiodarone is associated with an increased risk of sudden death." | 9.06 | Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia. ( Buxton, AE; Flores, BT; Josephson, ME; Marchlinski, FE; Miller, JM; Vassallo, JA, 1986) |
| "A case is presented in which amiodarone was administered to suppress paroxysmal atrial fibrillation in a patient with an idiopathic cardiomyopathy." | 8.79 | Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. ( Curwin, JH; Sachs, RG; Winters, SL, 1997) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 7.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "Although amiodarone appears to have few pro-arrhythmic effects, torsade de pointes (TdP) has been observed during long-term drug administration, usually in conjunction with electrolyte disturbances, a change in drug dosage, or concomitant drug therapy." | 7.73 | Torsade de pointes induced by short-term oral amiodarone therapy. ( Ahn, JC; Kim, YH; Lim, HE; Pak, HN; Song, WH, 2006) |
| "Five cases of amiodarone-induced polymorphous ventricular tachycardia (torsade de pointes) are presented." | 7.66 | Amiodarone-induced polymorphous ventricular tachycardia. ( Agmon, J; Arditti, A; Kracoff, O; Lewin, RF; Sclarovsky, S; Strasberg, B, 1983) |
| "A patient with the familial syndrome of Q-T prolongation, ventricular arrhythmias, and syncope was effectively treated with amiodarone." | 7.66 | Effective management of the long q-t syndrome with amiodarone. ( Bashour, T; Cheng, TO; Jokhadar, M, 1981) |
| "The initial arrhythmia was 2/1 atrial flutter (n = 4), 1/1 atrial flutter (n = 2) and atrial fibrillation (n = 1)." | 5.31 | [Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis]. ( Aouate, P; Dubois-Randé, JL; Elbaz, N; Fontaine, G; Frank, R; Klug, D; Lacotte, J; Lelouche, D; Raguin, D; Tonet, J, 2002) |
| "The effects of two regimens for the initiation of amiodarone therapy were compared in 92 patients with inducible sustained ventricular tachycardia (VT) at baseline electrophysiologic testing." | 5.07 | A comparison of standard and high-dose regimens for the initiation of amiodarone therapy. ( Kadish, A; Morady, F; Summitt, J, 1992) |
| "Induction of rapid ventricular tachycardia or fibrillation during therapy with amiodarone is associated with an increased risk of sudden death." | 5.06 | Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia. ( Buxton, AE; Flores, BT; Josephson, ME; Marchlinski, FE; Miller, JM; Vassallo, JA, 1986) |
| "A case is presented in which amiodarone was administered to suppress paroxysmal atrial fibrillation in a patient with an idiopathic cardiomyopathy." | 4.79 | Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate. ( Curwin, JH; Sachs, RG; Winters, SL, 1997) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 3.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "Although amiodarone appears to have few pro-arrhythmic effects, torsade de pointes (TdP) has been observed during long-term drug administration, usually in conjunction with electrolyte disturbances, a change in drug dosage, or concomitant drug therapy." | 3.73 | Torsade de pointes induced by short-term oral amiodarone therapy. ( Ahn, JC; Kim, YH; Lim, HE; Pak, HN; Song, WH, 2006) |
| "A 55-year-old patient with inferior wall infarction was treated effectively for ventricular tachycardia with high-dose oral amiodarone loading regimen (5 g within 16 hours)." | 3.68 | Antiadrenergic cardiovascular adverse effects of high-dose amiodarone loading regimen. ( Frey, B; Schmidinger, H; Steurer, G, 1992) |
| "ES was, therefore, of diagnostic value in more than half of the patients with syncope of unknown cause and long-term treatment based on ES was successful in the prevention of S (remission rate of 93% in patients treated with amiodarone or pacemaker)." | 3.67 | [Usefulness of the electrophysiologic study in the prognostic evaluation of patients with syncope of uncertain origin]. ( Bernardi, G; Feruglio, GA; Fontanelli, A; Gianfagna, P; Proclemer, A, 1987) |
| "Five cases of amiodarone-induced polymorphous ventricular tachycardia (torsade de pointes) are presented." | 3.66 | Amiodarone-induced polymorphous ventricular tachycardia. ( Agmon, J; Arditti, A; Kracoff, O; Lewin, RF; Sclarovsky, S; Strasberg, B, 1983) |
| "A patient with the familial syndrome of Q-T prolongation, ventricular arrhythmias, and syncope was effectively treated with amiodarone." | 3.66 | Effective management of the long q-t syndrome with amiodarone. ( Bashour, T; Cheng, TO; Jokhadar, M, 1981) |
| "A long Q-T interval syndrome is described, followed by "torsade de pointe" and by irriducible ventricular fibrillation that is ascribed to a badly conducted therapy with amiodarone, in a patient affected by mitral valve disease, microcitaemia and hemolitic intercurrent moderate jaundice." | 3.66 | ["T'orsade de pointe" and amiodarone (author's transl)]. ( Guerricchio, G; Scandiffio, T; Veglia, L, 1978) |
| "Syncope was associated with increased mortality risk in SCD-HeFT regardless of treatment arm (placebo, amiodarone, or ICD)." | 2.73 | Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. ( Anderson, J; Bardy, GH; Hellkamp, AS; Johnson, G; Lee, KL; Mark, DB; Olshansky, B; Packer, D; Poole, JE, 2008) |
| "An elderly woman had ventricular tachycardia, and her defibrillator failed to discharge." | 1.51 | Wide-QRS Tachycardia in an 89-Year-Old Woman With an ICD. ( Glancy, DL; Kawji, MM, 2019) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but potentially lethal inherited arrhythmia syndrome induced by adrenergic stress." | 1.48 | A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. ( Duan, H; Hua, Y; Li, Y; Lu, Y; Qiao, L; Wang, C; Yan, S; Zhou, K, 2018) |
| "Ventricular tachycardia is a life threatening cardiac arrhythmia." | 1.46 | Fatal monomorphic ventricular tachycardia in a semi-urban setting in Cameroon: a case report. ( Dikoume, L; Luchuo, EB; Nkoke, C, 2017) |
| "Recent infection was present in 40." | 1.39 | Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance. ( Ajrouche, R; Al-Hajje, A; Awada, S; El-Helou, N; Rachidi, S; Salameh, P; Zein, S, 2013) |
| "Syncope may be a manifestation of pulmonary embolism." | 1.35 | Entrapment of a floating thrombus in the right atrium by persistent Chiari's network: a barrier to massive pulmonary embolism. ( Colizzi, C; Lombardo, A; Pennestrì, F; Rizzello, V, 2009) |
| "Sustained monomorphic ventricular tachycardia was defined as a tachycardia with uninterrupted duration or rapid recurrence despite automatic internal cardiac defibrillator therapy for at least 5 minutes before amiodarone treatment, monomorphic morphology, rate greater than 120 beats/min, QRS duration greater than 120 ms, and subsequently determined to be ventricular tachycardia by ECG criteria (eg, atrioventricular dissociation), implanted device interrogation, or formal electrophysiology study." | 1.33 | Amiodarone is poorly effective for the acute termination of ventricular tachycardia. ( deSouza, IS; Marill, KA; Nishijima, DK; Ruskin, JN; Setnik, GS; Stair, TO, 2006) |
| "All arrhythmias were treated successfully by pacemaker/ICD implantation, radiofrequency catheter ablation and/or medications." | 1.33 | The utility of implantable loop recorders for diagnosing unexplained syncope in 100 consecutive patients: five-year, single-center experience. ( Cohen, T; Inamdar, V; Juang, G; Mehta, S, 2006) |
| "The initial arrhythmia was 2/1 atrial flutter (n = 4), 1/1 atrial flutter (n = 2) and atrial fibrillation (n = 1)." | 1.31 | [Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis]. ( Aouate, P; Dubois-Randé, JL; Elbaz, N; Fontaine, G; Frank, R; Klug, D; Lacotte, J; Lelouche, D; Raguin, D; Tonet, J, 2002) |
| "Arrhythmogenic right ventricular dysplasia is an inherited, progressive condition." | 1.31 | Arrhythmogenic right ventricular dysplasia. An illustrated review highlighting developments in the diagnosis and management of this potentially fatal condition. ( Fisher, NG; Gilbert, TJ, 2000) |
| "Although syncope is a frequent clinical entity, the evaluation and treatment of patients with syncope without a clear etiology still remains undefined." | 1.30 | [Patients with structural heart disease, syncope of unknown etiology and inducible ventricular arrhythmias treated with implantable defibrillators]. ( Aguinaga, L; Anguera, I; Brugada, J; Matas, M; Mont, L; Valentino, M, 1998) |
| "Amiodarone was clinically useful in 32 (68%) patients." | 1.28 | Use of amiodarone for short-term and adjuvant therapy in young patients. ( Benson, DW; Deal, BJ; Pongiglione, G; Strasburger, JF, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (25.00) | 18.7374 |
| 1990's | 10 (22.73) | 18.2507 |
| 2000's | 13 (29.55) | 29.6817 |
| 2010's | 8 (18.18) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Kawji, MM | 1 |
| Glancy, DL | 1 |
| Arias, MA | 1 |
| Pachón, M | 1 |
| Loughlin, G | 1 |
| Mazzanti, A | 1 |
| Guz, D | 1 |
| Trancuccio, A | 1 |
| Pagan, E | 1 |
| Kukavica, D | 1 |
| Chargeishvili, T | 1 |
| Olivetti, N | 1 |
| Biernacka, EK | 1 |
| Sacilotto, L | 1 |
| Sarquella-Brugada, G | 1 |
| Campuzano, O | 1 |
| Nof, E | 1 |
| Anastasakis, A | 1 |
| Sansone, VA | 1 |
| Jimenez-Jaimez, J | 1 |
| Cruz, F | 1 |
| Sánchez-Quiñones, J | 1 |
| Hernandez-Afonso, J | 1 |
| Fuentes, ME | 1 |
| Średniawa, B | 1 |
| Garoufi, A | 1 |
| Andršová, I | 1 |
| Izquierdo, M | 1 |
| Marinov, R | 1 |
| Danon, A | 1 |
| Expósito-García, V | 1 |
| Garcia-Fernandez, A | 1 |
| Muñoz-Esparza, C | 1 |
| Ortíz, M | 1 |
| Zienciuk-Krajka, A | 1 |
| Tavazzani, E | 1 |
| Monteforte, N | 1 |
| Bloise, R | 1 |
| Marino, M | 1 |
| Memmi, M | 1 |
| Napolitano, C | 1 |
| Zorio, E | 1 |
| Monserrat, L | 1 |
| Bagnardi, V | 1 |
| Priori, SG | 1 |
| Nkoke, C | 1 |
| Luchuo, EB | 1 |
| Dikoume, L | 1 |
| Duan, H | 1 |
| Lu, Y | 1 |
| Yan, S | 1 |
| Qiao, L | 1 |
| Hua, Y | 1 |
| Li, Y | 1 |
| Zhou, K | 1 |
| Wang, C | 1 |
| El-Helou, N | 1 |
| Al-Hajje, A | 1 |
| Ajrouche, R | 1 |
| Awada, S | 1 |
| Rachidi, S | 1 |
| Zein, S | 1 |
| Salameh, P | 1 |
| Stiefelhagen, P | 1 |
| Beyer, A | 1 |
| Ganti, B | 1 |
| Majkrzak, A | 1 |
| Theyyunni, N | 1 |
| Gopinathannair, R | 1 |
| Mazur, A | 1 |
| Olshansky, B | 2 |
| Keivanidou, A | 1 |
| Arnaoutoglou, C | 1 |
| Krommydas, A | 1 |
| Papanikolaou, G | 1 |
| Tsiptses, K | 1 |
| Chrisopoulos, C | 1 |
| Kirpizidis, C | 1 |
| Ross, JJ | 1 |
| Britton, KA | 1 |
| Desai, AS | 1 |
| Stevenson, WG | 2 |
| D'Ascenzi, F | 1 |
| Iadanza, A | 1 |
| Zacà, V | 1 |
| Pierli, C | 1 |
| Mondillo, S | 1 |
| Willan, AR | 1 |
| Chen, EB | 1 |
| Cook, RJ | 1 |
| Lin, DY | 1 |
| Aouate, P | 1 |
| Elbaz, N | 1 |
| Klug, D | 1 |
| Lacotte, J | 1 |
| Raguin, D | 1 |
| Frank, R | 1 |
| Lelouche, D | 1 |
| Dubois-Randé, JL | 1 |
| Tonet, J | 1 |
| Fontaine, G | 1 |
| Kozák, M | 1 |
| Izákovicová Hollá, L | 1 |
| Krivan, L | 1 |
| Vasků, A | 1 |
| Sepsi, M | 1 |
| Semrád, B | 1 |
| Vácha, J | 1 |
| Marill, KA | 1 |
| deSouza, IS | 1 |
| Nishijima, DK | 1 |
| Stair, TO | 1 |
| Setnik, GS | 1 |
| Ruskin, JN | 1 |
| Inamdar, V | 1 |
| Mehta, S | 1 |
| Juang, G | 1 |
| Cohen, T | 1 |
| Lim, HE | 1 |
| Pak, HN | 1 |
| Ahn, JC | 1 |
| Song, WH | 1 |
| Kim, YH | 1 |
| Davis, JE | 1 |
| Curtis, LA | 1 |
| Rashid, H | 1 |
| Rizzello, V | 1 |
| Lombardo, A | 1 |
| Colizzi, C | 1 |
| Pennestrì, F | 1 |
| Poole, JE | 1 |
| Johnson, G | 1 |
| Anderson, J | 1 |
| Hellkamp, AS | 1 |
| Packer, D | 1 |
| Mark, DB | 1 |
| Lee, KL | 1 |
| Bardy, GH | 1 |
| Morady, F | 2 |
| Shen, E | 1 |
| Schwartz, A | 1 |
| Hess, D | 1 |
| Bhandari, A | 1 |
| Sung, RJ | 1 |
| Scheinman, MM | 1 |
| Sclarovsky, S | 1 |
| Lewin, RF | 1 |
| Kracoff, O | 1 |
| Strasberg, B | 1 |
| Arditti, A | 1 |
| Agmon, J | 1 |
| Bashour, T | 1 |
| Jokhadar, M | 1 |
| Cheng, TO | 1 |
| Makkar, RR | 1 |
| Fromm, BS | 1 |
| Steinman, RT | 1 |
| Meissner, MD | 1 |
| Lehmann, MH | 1 |
| Stevenson, LW | 1 |
| Middlekauff, HR | 1 |
| Saxon, LA | 1 |
| Rapezzi, C | 1 |
| Spirito, P | 1 |
| Winters, SL | 1 |
| Sachs, RG | 1 |
| Curwin, JH | 1 |
| Aguinaga, L | 1 |
| Mont, L | 1 |
| Anguera, I | 1 |
| Valentino, M | 1 |
| Matas, M | 1 |
| Brugada, J | 1 |
| Fisher, NG | 1 |
| Gilbert, TJ | 1 |
| Alboni, P | 1 |
| Veglia, L | 1 |
| Scandiffio, T | 1 |
| Guerricchio, G | 1 |
| Brochier, M | 1 |
| Fauchier, JP | 1 |
| Charbonnier, B | 1 |
| Latour, F | 1 |
| Perrotin, D | 1 |
| Steurer, G | 1 |
| Schmidinger, H | 1 |
| Frey, B | 1 |
| Summitt, J | 1 |
| Kadish, A | 1 |
| Pongiglione, G | 1 |
| Strasburger, JF | 1 |
| Deal, BJ | 1 |
| Benson, DW | 1 |
| Wyndham, CR | 1 |
| Proclemer, A | 1 |
| Gianfagna, P | 1 |
| Fontanelli, A | 1 |
| Bernardi, G | 1 |
| Feruglio, GA | 1 |
| Kracoff, OH | 1 |
| Ovsyshcher, I | 1 |
| Gueron, M | 1 |
| Marchlinski, FE | 1 |
| Buxton, AE | 1 |
| Miller, JM | 1 |
| Vassallo, JA | 1 |
| Flores, BT | 1 |
| Josephson, ME | 1 |
| Dorian, P | 1 |
| Waldecker, B | 1 |
| Brugada, P | 1 |
| Zehender, M | 1 |
| Stevenson, W | 1 |
| Den Dulk, K | 1 |
| Wellens, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reveal® In-Office Implants Study[NCT01168427] | 66 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| [NCT00000609] | Phase 3 | 0 participants | Interventional | 1997-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This objective estimates the proportion of patients having procedure-related complication requiring resolution by surgical intervention at 90 days post-implant procedure using Kaplan-Meier method. (NCT01168427)
Timeframe: From Implant to 90 days post-implant procedure
| Intervention | participants (Number) |
|---|---|
| Implant Cohort | 2 |
Report number of participants having procedure-related adverse events that meet the primary endpoint (requiring surgical intervention), and number of participants having other procedure-related adverse events (not requiring surgical intervention). (NCT01168427)
Timeframe: From Implant to 90 days post-implant procedure
| Intervention | participants (Number) | |
|---|---|---|
| AEs that meet the primary endpoint | Other procedure-related AEs | |
| Implant Cohort | 2 | 4 |
5 reviews available for amiodarone and Drop Attack
| Article | Year |
|---|---|
Syncope in congestive heart failure.
Topics: Aged; Aged, 80 and over; Amiodarone; Combined Modality Therapy; Defibrillators, Implantable; Electro | 2008 |
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Bepridil; Cardiovascular Agents; Disopyramid | 1993 |
Sudden death prevention in patients with advanced ventricular dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Death, Su | 1993 |
Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy. Management with intravenous magnesium sulfate.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathies; Humans; Infusions, | 1997 |
Role of invasive electrophysiologic testing in the management of life-threatening ventricular arrhythmias.
Topics: Amiodarone; Cardiac Pacing, Artificial; Death, Sudden; Electrocardiography; Electrophysiology; Heart | 1988 |
3 trials available for amiodarone and Drop Attack
| Article | Year |
|---|---|
Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Death, Sudden, Cardiac; Defibrillators, | 2008 |
A comparison of standard and high-dose regimens for the initiation of amiodarone therapy.
Topics: Aged; Amiodarone; Cardiac Pacing, Artificial; Drug Administration Schedule; Female; Heart Conduction | 1992 |
Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia.
Topics: Adult; Aged; Amiodarone; Death, Sudden; Drug Evaluation; Drug Therapy, Combination; Female; Follow-U | 1986 |
36 other studies available for amiodarone and Drop Attack
| Article | Year |
|---|---|
Wide-QRS Tachycardia in an 89-Year-Old Woman With an ICD.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Electrocardiogra | 2019 |
New Onset Recurrent Syncope Triggered by Fever.
Topics: Amiodarone; Coronary Angiography; Drug Therapy, Combination; Electric Countershock; Electrocardiogra | 2020 |
Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Amiodarone; Andersen Syndrome; Anti-Arrhythmia Agent | 2020 |
Fatal monomorphic ventricular tachycardia in a semi-urban setting in Cameroon: a case report.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cameroon; Electrocardiography; Fatal Outcome; Heart Rate; | 2017 |
A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
Topics: Amiodarone; Anti-Arrhythmia Agents; Child; Death, Sudden, Cardiac; Delayed Diagnosis; Electrocardiog | 2018 |
Adverse drug events associated with vitamin K antagonists: factors of therapeutic imbalance.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Anti-Inflammatory Agen | 2013 |
[Paroxysmal atrial fibrillation well controlled. Why the sudden patient syncope?].
Topics: Amiodarone; Atrial Fibrillation; Clopidogrel; Coronary Disease; Diagnosis, Differential; Drug Therap | 2015 |
A Perfect Storm: Tyrosine Kinase Inhibitor-Associated Polymorphic Ventricular Tachycardia.
Topics: Adenine; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Cardiotonic Agents; Electric Cou | 2017 |
Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents; Atrial Fibrillation; Ciprofloxacin; | 2009 |
Interactive medical case. The beat goes on.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Biopsy; Bundle-Branch Block; Cardiomyopathy, Dilated; Def | 2010 |
Subocclusion of the sinus node artery during coronary angioplasty: arrhythmological considerations.
Topics: Acute Coronary Syndrome; Amiodarone; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Atrial | 2010 |
Incremental net benefit in randomized clinical trials with quality-adjusted survival.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cost-Benefit Analysis; Health Care Costs; Heart Arrest; Humans; | 2003 |
[Atrial flutter with 1/1 nodo-ventricular conduction with amiodarone. From physiopathology to diagnosis].
Topics: Administration, Oral; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial | 2002 |
Endothelin-1 gene polymorphism in patients with malignant arrhythmias.
Topics: Aged; Amino Acid Sequence; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Defibrillators, | 2004 |
Amiodarone is poorly effective for the acute termination of ventricular tachycardia.
Topics: Aged; Aged, 80 and over; Amiodarone; Combined Modality Therapy; Dose-Response Relationship, Drug; El | 2006 |
The utility of implantable loop recorders for diagnosing unexplained syncope in 100 consecutive patients: five-year, single-center experience.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia | 2006 |
Torsade de pointes induced by short-term oral amiodarone therapy.
Topics: Administration, Oral; Adult; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillat | 2006 |
Idiopathic cardiac electrical storm.
Topics: Adrenergic beta-Antagonists; Amiodarone; Drug Therapy, Combination; Electrocardiography; Humans; Mal | 2009 |
Entrapment of a floating thrombus in the right atrium by persistent Chiari's network: a barrier to massive pulmonary embolism.
Topics: Adult; Amiodarone; Echocardiography, Transesophageal; Enzyme Inhibitors; Heart Atria; Heart Valves; | 2009 |
Long-term follow-up of patients with recurrent unexplained syncope evaluated by electrophysiologic testing.
Topics: Amiodarone; Electrophysiology; Female; Follow-Up Studies; Humans; Male; Mitral Valve Prolapse; Pacem | 1983 |
Amiodarone-induced polymorphous ventricular tachycardia.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Cardiac Pacing, Artificial; Electrocardiography | 1983 |
Effective management of the long q-t syndrome with amiodarone.
Topics: Adolescent; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Electrocardiography; Heart Ventricles; Hu | 1981 |
[Cardiac decompensation and syncope].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Heart Failure; Humans | 1994 |
[Therapy of arrhythmias in hypertrophic cardiomyopathy].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiomy | 1995 |
Assessment of the cardiac patient for fitness to drive: 1996 update.
Topics: Amiodarone; Arrhythmias, Cardiac; Automobile Driving; Defibrillators, Implantable; Electrocardiograp | 1996 |
[Patients with structural heart disease, syncope of unknown etiology and inducible ventricular arrhythmias treated with implantable defibrillators].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia | 1998 |
Arrhythmogenic right ventricular dysplasia. An illustrated review highlighting developments in the diagnosis and management of this potentially fatal condition.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventric | 2000 |
[The amiodarone-beta blockers combination could represent an alternative treatment in patients at risk for sudden death in which a benefit from implantable defibrillators has not been clearly demonstrated].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillat | 2002 |
["T'orsade de pointe" and amiodarone (author's transl)].
Topics: Amiodarone; Benzofurans; Female; Humans; Middle Aged; Mitral Valve Insufficiency; Syncope; Tachycard | 1978 |
[Beneficial effects of injectable amiodarone on syncope in Prinzmetal's angina].
Topics: Amiodarone; Angina Pectoris; Angina Pectoris, Variant; Benzofurans; Drug Evaluation; Humans; Infusio | 1976 |
Antiadrenergic cardiovascular adverse effects of high-dose amiodarone loading regimen.
Topics: Administration, Oral; Amiodarone; Cardiac Output, Low; Catecholamines; Humans; Male; Middle Aged; My | 1992 |
Use of amiodarone for short-term and adjuvant therapy in young patients.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Adult; Amiodarone; Arrhythmias, Cardi | 1991 |
[Usefulness of the electrophysiologic study in the prognostic evaluation of patients with syncope of uncertain origin].
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Arrhythmias, Cardiac; Electrocardiography; Female; Follo | 1987 |
Malignant course of a benign anomaly: myocardial bridging.
Topics: Adult; Amiodarone; Cardiomyopathies; Coronary Angiography; Diltiazem; Electrocardiography; Electroph | 1987 |
Syncope, tachycardia, and exertional dyspnea.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiac Catheterization; Coronary Disease; Dyspnea; Elect | 1985 |
Importance of modes of electrical termination of ventricular tachycardia for the selection of implantable antitachycardia devices.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Coronary Disease; Humans; Male; Middle | 1986 |